Since inflammation is an important element in the development, progression, and prognosis of PAD in CKD, future studies should investigate the impact of interventions to reduce FGF23 on inflammatory markers and, conversely, the impact of anti-inflammatory therapies on FGF23 levels. The gene discussed is FGF23; the disease is chronic kidney disease.